David Hughes Email & Phone Number

We provide ISO 13485 certified nano topology solutions for small bone PEEK implant manufacturers. In plain English, we make small bone PEEK implants better by preventing encapsulation and promoting rapid bone cell attachment. Our surface modification technologies have been used on more than 100,000 FDA-cleared spinal implants. Our solution is tested and proven.

Surfatek is an advanced nanotech surface company that creates and supplies nanoscale surfaces that deliver revolutionary performance - control of cell attachment to medical implants, 10X life extension for production tools, ceramic and organo-metallic water blocking coatings for electronics and other products. Surfatek’s and its medical subsidiary, PcoMed’s, nanotech surfaces and coatings transform medical implants, industrial products and production tools by creating performance that was not possible before: TruBōnTM Osteoblast Attachment Surfaces which prevent fibroblast encapsulation of spinal implants and generates true bone cell attachment. PH2ObicTM water resistant and waterproof surfaces protect electronics and other products particularly in harsh environments. ToolArmorTM, a multi-layer, nano-composite surface, extends the life of products and production tools such as injection molds and extrusion dies many fold.

Intelligent Innovation advises and supports growth companies and major international corporations in developing new products and technologies and sourcing advanced technology in multiple markets and technical areas. Clients include industrial companies and commercial companies with a significant concentration in medical devices. Intelligent Innovation also assists corporations in negotiating technology licenses and partnerships, distribution relationships and other partnerships, especially with companies in other countries. It's particular experience is in negotiating deals between Japanese companies and American and European companies.Intelligent Innovation also manages the design and manufacture of custom technical or process equipment for customers, with an emphasis on delivering advanced capabilities not available from other suppliers or advanced capabilities at significantly less cost than other suppliers.

Directed new medical surface/coatings business that emerged from venture capital purchase of Chameleon Scientific. Prepared it for sale by venture capital owners.

Maple Grove, Mn, Us

R4 was a vascular products company that developed an ultra-high pressure peripheral angioplasty balloon catheter and developed and sold a family of vascular catheters, several of which used proprietary non-thrombogenic coating technology. Brought in by venture capital owners to fix major cash drain on company and restructure operations. Renegotiated relationships with multiple vendors, refocused all development on proprietary peripheral balloon technology which gained FDA approval in 2012. Prepared company for sale of its high-value assets.

Chameleon created coatings and nano-surfaces that delivered revolutionary performance on implanted and indwelling medical devices, including: True cell attachment, 1000X more potent antimicrobial surfaces, polymer-free drug delivery and unbreakable pacing lead conductors. Stepped in as CEO when Chameleon's fundraising collapsed in Q3/2008 and the company had two months of cash on hand. Saved the company, its technology and its key technical staff during a very challenging period for medical technology companies. Engineered the sale of Chameleon to two venture capital groups in July 2010.

Neovex developed and provided continuous automated production technology for liquid pharmaceuticals and biotech products that dramatically reduced costs by cutting labor 80% or more, energy 65% or more, space 80% or more, streamlining quality assurance and control efforts and significantly reducing needed management and overhead. When coupled with automated form, fill, seal technology from a European partner, the resulting production system delivered unparalleled product safety by eliminating manual operations, with potential for human contact and error, and completely isolating solution production and packaging from the environment.

Vendôme, Centre-Val De Loire, Fr

Turned around medical oxygen equipment manufacturer by reorganizing R&D, introducing new R&D project management and staff assignment methods, cutting manufacturing costs dramatically, introducing new, highly competitive products and closing new contracts with large home care customers, including the company's first $10 million per year contract. Returned company to $40 million annual revenue from $28 million within 9 months. Increased volume, improved efficiencies and reduced manufacturing costs quickly returned the company to profitability and well above historical levels.

Deerfield, Illinois, Us

Directed development of new electron-beam method for safely and economically processing hazardous medical waste on site at hospitals. Assembled and directed multi-company team to develop low-cost, durable unit for sterilizing hazardous medical waste so that it could be disposed of as normal trash, thereby avoiding high cost and risk of medical waste transport and incineration's high cost and adverse environmental impact of releasing hydrochloric acid and dioxin into the atmosphere.Directed development of a telesales and specialized direct mail group within Baxter to effectively and economically serve small hospitals, clinics and physician offices that the company's hospital supply business and its sales force were unable to reach, thereby significantly expanding the market for the company's full line of hospital and medical products.Managed Physical Therapy Division's sales and marketing activities, new product development and new service development for its network of nearly 50 outpatient PT centers. Directed complete redesign of outpatient care delivery which produced improved patient care, faster patient throughput, elimination of patient wait time, increased facility utilization, a dramatic increase in patient and referring physician satisfaction which all resulted in reduced cost per patient and significantly increased profit per facility.

Started company to commercialize revolutionary catalytic technology for converting super-chlorinated chemical wastes to usable industrial chemicals. Generated start-up funding from B.F. Goodrich, the world's leading generator of super-chlorinated chemicals and waste at the time. Utilized underlying technology developed at and licensed from Allied-Signal.

Built corporate new business group for $6B Signal. Started three new businesses in recycling hazardous halogenated chemical wastes, solid state gas and chemical sensors and membrane separations. Directed development and application of the technologies underlying these businesses, including a revolutionary and proprietary catalytic technology for transforming halogenated chemical wastes into usable industrial chemicals, thereby avoiding incineration or disposal. Developed and introduced commercial products for each of the businesses within 12 months.

St Paul, Mn, Us

Manager in multiple business units, including Surgical Products and Commercial Graphics. Directed development of new graphic material technologies that expanded business into multiple new markets. Negotiated technology development and distribution partnerships to expand 3M technical capabilities and extend its market reach. Started and built a highly automated short-run graphics business that eventually generated more than $200 million in high-profit annual sales in new graphics markets for 3M.

Master Of Business Administration (M.B.A.), Business Administration

Ba, Political Science With Concentration In International Relations